Rocket Pharmaceuticals, Inc.
DE ˙ DB ˙ US77313F1066
2,44 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:9IP1 / Rocket Pharmaceuticals, Inc.
InstitutionGoldman Sachs Group Inc
Latest Disclosed Ownership1,721,116 shares
Latest Disclosed Value $ 6,161,594
Goldman Sachs Group Inc ownership in 9IP1 / Rocket Pharmaceuticals, Inc.

On May 15, 2026 - Goldman Sachs Group Inc filed a 13F-HR form disclosing ownership of 1,721,116 shares of Rocket Pharmaceuticals, Inc. (DE:9IP1) valued at $4,844,942 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 936,594 shares of Rocket Pharmaceuticals, Inc.. This represents a change in shares of 83.76% during the quarter. The current value of the position is $4,199,523 USD.

Goldman Sachs Group Inc has a history of taking positions in derivatives of the underlying security (9IP1) in the form of stock options. The firm currently holds call options representing 140,000 of underlying shares valued at $501,200 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:9IP1 / Rocket Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,721,116 784,522 83.76 6,162 87.44 0.0007
2026-02-10 2025-12-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 936,594 -334,499 -26.32 3,287 -20.66 0.0004
2025-11-14 2025-09-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,271,093 -304,375 -19.32 4,144 7.36 0.0005
2025-08-14 2025-06-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,575,468 579,778 58.23 3,860 -41.89 0.0005
2025-06-27 2025-03-31 13F/A-2 ROCKET PHARMACEUTICALS CMN 77313F106 995,690 192,905 24.03 6,641 -34.19 0.0011
2025-05-16 2025-03-31 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 995,690 192,905 6,641 0.0011
2025-05-09 2025-03-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 995,690 192,905 6,641 0.0002
2025-02-11 2024-12-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 802,785 378,712 89.30 10,091 28.84 0.0016
2024-11-14 2024-09-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 424,073 -271,835 -39.06 7,833 -47.72 0.0013
2024-08-13 2024-06-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 695,908 265,033 61.51 14,983 29.08 0.0025
2024-05-15 2024-03-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 430,875 -163,790 -27.54 11,608 -34.87 0.0021
2024-05-14 2023-12-31 13F/A-2 ROCKET PHARMACEUTICALS CMN 77313F106 594,665 64,946 12.26 17,822 64.21 0.0033
2024-03-01 2023-12-31 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 594,665 64,946 17,822 0.0032
2024-02-13 2023-12-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 594,665 64,946 17,822 0.0008
2024-05-15 2023-09-30 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 529,719 -911,191 -63.24 10,854 -62.09 0.0023
2023-11-14 2023-09-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 529,719 -911,191 10,854 0.0022
2024-05-14 2023-06-30 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 1,440,910 -210,817 -12.76 28,631 1.19 0.0061
2023-08-15 2023-06-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,440,910 -210,817 28,631 0.0058
2024-05-14 2023-03-31 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 1,651,727 622,563 60.49 28,294 40.49 0.0065
2023-05-11 2023-03-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,651,727 622,563 28,294 0.0060
2024-05-14 2022-12-31 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 1,029,164 -1,007,480 -49.47 20,141 62,837.50 0.0049
2023-02-13 2022-12-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,029,164 -1,007,480 20,141 0.0045
2024-05-14 2022-09-30 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 2,036,644 533,749 35.51 33 60.00 0.0082
2022-11-14 2022-09-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 2,036,644 533,749 32,505 0.0075
2024-05-14 2022-06-30 13F/A-2 ROCKET PHARMACEUTICALS CMN 77313F106 1,502,895 -48,879 -3.15 21 -99.92 0.0052
2022-08-18 2022-06-30 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 1,502,895 -48,879 20,680 0.0047
2022-08-15 2022-06-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,502,895 -48,879 20,680 0.0014
2022-05-16 2022-03-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,551,774 886,919 133.40 24,612 69.57 0.0052
2022-02-17 2021-12-31 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 664,855 -302,742 -31.29 14,514 -49.82 0.0029
2022-02-14 2021-12-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 664,855 -302,742 14,514 0.0008
2022-01-20 2021-09-30 13F/A-1 ROCKET PHARMACEUTICALS CMN 77313F106 967,597 225,292 30.35 28,922 -12.03 0.0061
2021-11-10 2021-09-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 967,597 225,292 28,922 0.0018
2021-08-13 2021-06-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 742,305 -370,530 -33.30 32,877 -33.42 0.0074
2021-05-17 2021-03-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,112,835 168,875 17.89 49,376 -4.62 0.0125
2021-02-12 2020-12-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 943,960 -183,640 -16.29 51,767 100.83 0.0133
2020-11-13 2020-09-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 1,127,600 463,619 69.82 25,777 85.49 0.0073
2020-08-12 2020-06-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 663,981 -112,536 -14.49 13,897 28.30 0.0042
2020-05-15 2020-03-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 776,517 87,271 12.66 10,832 -30.95 0.0038
2020-02-14 2019-12-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 689,246 40,774 6.29 15,688 107.65 0.0040
2019-11-14 2019-09-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 648,472 52,581 8.82 7,555 -15.47 0.0022
2019-08-14 2019-06-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 595,891 -74,104 -11.06 8,938 -23.94 0.0026
2019-05-15 2019-03-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 669,995 -63,141 -8.61 11,751 8.15 0.0036
2019-02-14 2018-12-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 733,136 195,859 36.45 10,865 -17.86 0.0035
2018-11-14 2018-09-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 537,277 537,277 13,228 0.0034
2018-08-14 2018-06-30 13F ROCKET PHARMACEUTICALS CMN 77313F106 0 -134,560 -100.00 0 -100.00
2018-05-15 2018-03-31 13F ROCKET PHARMACEUTICALS CMN 77313F106 134,560 134,560 2,523 0.0006
2017-11-14 2017-09-30 13F INOTEK PHARMACEUTICALS CMN 45780V102 0 -173,690 -100.00 0 -100.00
2017-08-14 2017-06-30 13F INOTEK PHARMACEUTICALS CMN 45780V102 173,690 114,932 195.60 330 179.66 0.0001
2017-05-18 2017-03-31 13F/A-1 INOTEK PHARMACEUTICALS CMN 45780V102 58,758 -317,869 -84.40 118 -94.86 0.0000
2017-05-15 2017-03-31 13F INOTEK PHARMACEUTICALS CMN 45780V102 58,758 118
2017-02-14 2016-12-31 13F INOTEK PHARMACEUTICALS CMN 45780V102 376,627 161,517 75.09 2,297 12.65 0.0006
2016-11-14 2016-09-30 13F INOTEK PHARMACEUTICALS CMN 45780V102 215,110 158,810 282.08 2,039 386.63 0.0006
2016-08-15 2016-06-30 13F INOTEK PHARMACEUTICALS CMN 45780V102 56,300 9,903 21.34 419 22.16 0.0001
2016-05-13 2016-03-31 13F INOTEK PHARMACEUTICALS CMN 45780V102 46,397 46,397 0.00 343 0.0001
2015-11-13 2015-09-30 13F INOTEK PHARMACEUTICALS CMN 45780V102 0 -18,440 -100.00 0 -100.00
2015-08-14 2015-06-30 13F INOTEK PHARMACEUTICALS CMN 45780V102 18,440 18,440 90 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ROCKET PHARMACEUTICALS CMN Call 140,000 501 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2017-05-18 2017-03-31 13F/A INOTEK PHARMACEUTICALS CMN Put 0 -100.00 0 -100.00 n/a n/a n/a
2017-02-14 2016-12-31 13F INOTEK PHARMACEUTICALS CMN Put 361,000 0.00 2,202 -35.65 n/a n/a n/a
2016-11-14 2016-09-30 13F INOTEK PHARMACEUTICALS CMN Put 361,000 3,422 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.